Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Phase 2 Completed 15 enrolled Aaron Cypess National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelBasic science

Summary

This study will test the hypothesis that human brown adipose tissue (BAT) can be activated using a β3-adrenergic receptor (AR) agonist. The efficacy of β3-AR agonist will be compared with cold exposure, which we have already shown can activate human BAT, as well as a placebo control.

Timeline

Start: 2013-02
Primary completion: 2014-10
Completion: 2014-10

Outcome

Met primary endpoint

paper Mirabegron led to higher BAT metabolic activity PMID 25565203 ↗

paper in all twelve healthy male subjects (p = 0.001) PMID 25565203 ↗

registry analysis (equivalence test); Placebo vs beta3-adrenergic Receptor (AR); p = 0.001; Wilcoxon sign-ranks test NCT01783470 ↗

Publications

Results Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elia E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015 Jan 6;21(1):33-8. doi: 10.1016/j.cmet.2014.12.009.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirabegron	Other / unclassified	200 mg	Oral